Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two pharmaceutical drugs, buspirone and escitalopram, used primarily in the management of anxiety and depressive disorders. Buspirone is an anxiolytic agent that acts as a serotonin 5-HT1A receptor partial agonist, with minor activity at dopamine receptors. It is primarily indicated for generalized anxiety disorder and as a second-line treatment for depression[4][3]. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases serotonin levels in the brain by inhibiting its reuptake into presynaptic neurons; it is approved for major depressive disorder and generalized anxiety disorder[7][3]. The combination may be considered when monotherapy does not provide adequate symptom control. However, co-administration increases the risk of serotonin syndrome due to additive serotonergic effects[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on buspirone + escitalopram.